Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Non-Melanoma Skin Cancer (NMSC) 1Neoplasms 1Hypogonadism 1Fatigue 1Eunuchism 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Gels × 1 year × Clear all
NCT04301765 2026-03-31

TEMEC

Seattle Institute for Biomedical and Clinical Research

Phase 2 Recruiting
230 enrolled

Eunuchism, Fatigue, Hypogonadism, Neoplasms

NCT07201376 2026-02-06

PPIX

Dartmouth-Hitchcock Medical Center

Recruiting
125 enrolled
Dermatologic

Non-Melanoma Skin Cancer (NMSC)

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Mayo Clinic

Phase 2 Terminated
65 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡